Tetraphase Pharmaceuticals Inc
Most Recent
Analysts’ Ratings for Sarepta Therapeutics and Peers in April
Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.
How Analysts View Tetraphase Pharmaceuticals in April 2018
Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.
